Aggressive Management of Pulmonary Mucormycosis Necrotizing Fasciitis in a Post-Liver Transplant Patient.

Pulmonary mucormycosis (PM) is a severe fungal infection that predominantly affects immunocompromised and diabetic individuals, and it is associated with a high mortality rate, particularly in cases of disseminated disease. We present the case of a 29-year-old liver transplant recipient who developed aggressive PM, confirmed through bronchoalveolar lavage. Treatment involved liposomal amphotericin B, followed by surgical debridement and right pneumonectomy.

Goals of Frail Older People Living With Chronic Kidney Disease: A Mixed Methods Study.

Background: Frail older adults with chronic kidney disease (CKD) have complex care needs, and their priorities may differ from those assumed by healthcare providers. Understanding their goals is crucial to delivering person-centred care. This study aimed to identify and categorize the goals of this population and determine any association with participants' frailty status, quality of life, and CKD stage.

Incidence and survival of interstitial lung diseases in the UK in 2010-2019.

Background: With the introduction of the antifibrotic drugs targeting progressive pulmonary fibroses, it becomes imperative to provide reliable contemporary estimates of the most common interstitial lung diseases. We aimed to provide contemporary estimates of the incidence and survival of idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP) and connective tissue disease-associated interstitial lung disease (CTD-ILDs), and to compare their survival to that of the general population. To do this we have used data extracted from the Optimum Patient Care Research Database (OPCRD).

Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: A systematic review.

Introduction: Acute myeloid leukaemia (AML) is a disease of the older person. Due to the demands of intensive chemotherapy, there is a significant risk of over or undertreatment, leading to either iatrogenic harm or missed windows of opportunity for remission or cure. Better tools to aid clinical decision making and risk stratify patients are needed.

Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets.

Background: Idiopathic pulmonary fibrosis (IPF) is a rare, incurable lung disease with a median survival of 3-5 years after diagnosis. Treatment options are limited. Genetic association studies can identify new genes involved in disease that might represent potential new drug targets, and it has been shown that drug targets with support from genetic studies are more likely to be successful in clinical development.